Incremental benefits of male HPV vaccination: Accounting for inequality in population uptake

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Smith, Megan A ^a,b   Canfell, Karen ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; AUSTRALIA; CONTROLLED STUDY; DISEASE TRANSMISSION; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNIZATION; INFECTION RATE; MALE; PAPILLOMAVIRUS INFECTION; POPULATION RESEARCH; POST EXPOSURE PROPHYLAXIS; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SEXUALITY; SOCIAL STATUS; UNITED STATES; VACCINATION; ADOLESCENT; BIOLOGICAL MODEL; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS; SOCIOECONOMICS; TREATMENT OUTCOME; VIROLOGY;

ADOLESCENT; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MALE; MODELS, BIOLOGICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME; VACCINATION;

EID: 84905457681     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101048     Document Type: Article

References (54)

1. Centers for Disease Control and Prevention (2011) Recommendations on the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR MorbMortalWklyRep 60: 1705-1708.
2. National Advisory Committee on Immunization (2012) Update On Human Papillomavirus (HPV) Vaccines. Can CommunDis Rep 38.
3. Pharmaceutical Benefits Advisory Committee (2011) November 2011 PBAC Outcomes - Positive Recommendations.
4. European Centre for Disease Prevention and Control (2012) Introduction of HPV vaccines in EU countries - an update. Stockholm, Sweden.
5. Bundesministerium für Gesundheit (Austrian Federal Ministry for Health) (2013) Ausbau Kinder-Impfprogramm: Die Aufnahme der Impfung gegen Humane Papilloma-Viren (HPV) [Expanding children's vaccination program: the inclusion of vaccination against human papilloma virus (HPV)].
6. Canfell K, Chesson H, Kulasingam SL, Berkhof J, Diaz M, et al. (2012) Modeling Preventative Strategies against Human Papillomavirus-Related Disease in Developed Countries. Vaccine 30 Suppl 5: F157-F167.
7. Smith MA, Lew JB, Walker RJ, Brotherton JM, Nickson C, et al. (2011) The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. Vaccine 29: 9112-9122.
8. Brisson M, van de Velde N, Franco EL, Drolet M, Boily MC (2011) Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J Infect Dis 204: 372-376.
9. Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE (2011) The cost-effectiveness of male HPV vaccination in the United States. Vaccine 29: 8443-8450.
10. Bogaards JA, Kretzschmar M, Xiridou M, Meijer CJ, Berkhof J, et al. (2011) Sex-specific immunization for sexually transmitted infections such as human papillomavirus: insights from mathematical models. PLoS Med 8: e1001147.
11. Kessels SJ, Marshall HS, Watson M, Braunack-Mayer AJ, Reuzel R, et al. (2012) Factors associated with HPV vaccine uptake in teenage girls: A systematic review. Vaccine.
12. Fisher H, Trotter CL, Audrey S, MacDonald-Wallis K, Hickman M (2013) Inequalities in the uptake of human papillomavirus vaccination: a systematic review and meta-analysis. Int J Epidemiol 42: 896-908.
13. Dempsey AF, Schaffer SE, Cohn LM (2012) Follow-up analysis of adolescents partially vaccinated against human papillomavirus. J Adolesc Health 50: 421-423.
14. Gilkey MB, Moss JL, McRee A-L, Brewer NT (2012) Do correlates of HPV vaccine initiation differ between adolescent boys and girls? Vaccine 30: 5928-5934.
15. Hamlish T, Clarke L, Alexander KA (2012) Barriers to HPV immunization for African American adolescent females. Vaccine 30: 6472-6476.
16. Keenan K, Hipwell A, Stepp S (2012) Race and sexual behavior predict uptake of the human papillomavirus vaccine. Health Psychology 31: 31-34.
17. Liddon NC, Leichliter JS, Markowitz LE (2012) Human papillomavirus vaccine and sexual behavior among adolescent and young women. Am J Prev Med 42: 44-52.
18. Sadigh G, Dempsey AF, Ruffin M, Resnicow K, Carlos RC (2012) National patterns in human papillomavirus vaccination: an analysis of the National Survey of Family Growth. Hum Vaccin Immunother 8: 234-242.
19. Musto R, Siever J, Johnston J, Seidel J, Rose M, et al. (2013) Social equity in Human Papillomavirus vaccination: a natural experiment in Calgary Canada. BMC Public Health 13: 640.
20. Barbaro B, Brotherton JM, Gertig DM (2012) Human papillomavirus vaccination and cervical cancer screening by socioeconomic status, Victoria. Med J Aust 196: 445.
21. Kumar VM, Whynes DK (2011) Explaining variation in the uptake of HPV vaccination in England. BMC Public Health 11: 172.
22. Marlow LA (2011) HPV vaccination among ethnic minorities in the UK: knowledge, acceptability and attitudes. Br J Cancer 105: 486-492.
23. Liddon N, Hood J, Wynn BA, Markowitz LE (2010) Acceptability of human papillomavirus vaccine for males: a review of the literature. J Adolesc Health 46: 113-123.
24. Ogilvie GS, Remple VP, Marra F, McNeil SA, Naus M, et al. (2008) Intention of parents to have male children vaccinated with the human papillomavirus vaccine. Sex Transm Infect 84: 318-323.
25. Reiter PL, Gilkey MB, Brewer NT (2013) HPV vaccination among adolescent males: Results from the National Immunization Survey-Teen. Vaccine 31: 2816-2821.
26. Reiter PL, McRee AL, Gottlieb SL, Brewer NT (2010) HPV vaccine for adolescent males: acceptability to parents post-vaccine licensure. Vaccine 28: 6292-6297.
27. Reiter PL, McRee AL, Kadis JA, Brewer NT (2011) HPV vaccine and adolescent males. Vaccine 29: 5595-5602.
28. Zhang SK, Pan XF, Wang SM, Yang CX, Gao XH, et al. (2013) Perceptions and acceptability of HPV vaccination among parents of young adolescents: A multicenter national survey in China. Vaccine 31: 3244-3249.
29. Lenselink CH, Gerrits MM, Melchers WJ, Massuger LF, van Hamont D, et al. (2008) Parental acceptance of Human Papillomavirus vaccines. Eur J Obstet Gynecol Reprod Biol 137: 103-107. (Pubitemid 351625432)
30. Shafer LA, Jeffrey I, Elias B, Shearer B, Canfell K, et al. (2013) Quantifying the impact of dissimilar HPV vaccination uptake among Manitoban school girls by ethnicity using a transmission dynamic model. Vaccine 31: 4848-4855.
31. Malagón T, Joumier V, Boily M-C, Van de Velde N, Drolet M, et al. (2013) The impact of differential uptake of HPV vaccine by sexual risks on health inequalities: A model-based analysis. Vaccine 31: 1740-1747.
32. Commission on Social Determinants of Health (2008) Closing the gap in a generation: health equity through action on the social determinants of health. Final Report of the Commission on Social Determinants of Health. Geneva.
33. Whitehead M (1992) The concepts and principles of equity and health. Int J Health Serv 22: 429-445.
34. Smith MA, Canfell K, Brotherton JM, Lew JB, Barnabas RV (2008) The predicted impact of vaccination on human papillomavirus infections in Australia. Int J Cancer 123: 1854-1863.
35. Walker R, Nickson C, Lew JB, Smith M, Canfell K (2012) A revision of sexual mixing matrices in models of sexually transmitted infection. StatMed 31: 3419-3432.
36. Department of Health and Ageing (2011) Human Papillomavirus (HPV): Immunise Australia program. Department of Health & Ageing.
37. Australian Bureau of Statistics (2008) Population by Age and Sex, Australian States and Territories, Jun 2002 to Jun 2007.
38. Centers for Disease Control and Prevention (2011) National, State and Local Area Vaccination Coverage among Adolescents Aged 13 through 17 Years - United States 2010. Morbidity and Mortality Weekly Report 60: 1117-1123.
39. U. S. Census Bureau (2011) Annual Estimates of the Resident Population for the United States, Regions, States, and Puerto Rico: April 1, 2010 to July 1, 2011 (NST-EST2011-01).
40. Wagstaff A, Paci P, van Doorslaer E (1991) On the measurement of inequalities in health. Soc Sci Med 33: 545-557.
41. Preston SH, Haines MR, Pamuk E (1981) Effects of Industrialization and Urbanization of Mortality in Developed Countries. IUSSP 19th International population Conference. Manila: IUSSP. pp. 233-254.
42. Leclerc A, Lert F, Fabien C (1990) Differential mortality: some comparisons between England and Wales, Finland and France, based on inequality measures. Int J Epidemiol 19: 1001-1010.
43. Garnett GP, Kim JJ, French K, Goldie SJ (2006) Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 24 Suppl 3: S3/178-S173/186.
44. Garnett GP (2005) Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J InfectDis 191 Suppl 1: S97-106.
45. Smith L, Grigg M, Davies L, Reilly J, Laukau S (2012) HPV Immunisation Programme Implementation Evaluation. Wellington, NZ.
46. Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, et al. (2013) Annual Report to the Nation on the Status of Cancer, 1975-2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)-Associated Cancers and HPV Vaccination Coverage Levels. J Natl Cancer Inst 105: 175-201.
47. Smith M, Walker R, Canfell K (2013) National Cervical Screening Programme Annual Report (2010-2011). Wellington, NZ.
48. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, et al. (2012) Global burden of human papillomavirus and related diseases. Vaccine 30 Suppl 5: F12-23.
49. Ali H, Donovan B, Wand H, Read TR, Regan DG, et al. (2013) Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 346: f2032.
50. Palefsky JM (2010) Human Papillomavirus-Related Disease in Men: Not Just a Women's Issue. Journal of Adolescent Health 46: S12-S19.
51. Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, et al. (2004) Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 101: 270-280. (Pubitemid 38890829)
52. Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, et al. (2011) Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 11: 39-44.
53. Kim JJ (2010) Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 10: 845-852.
54. Simatherai D, Bradshaw CS, Fairley CK, Bush M, Heley S, et al. (2009) What men who have sex with men think about the human papillomavirus vaccine. Sex Transm Infect 85: 148-149.